N^α-(tert-butoxycarbonyl)allylglycine-N-methoxy-N-methylamide | 603992-62-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N^α-(tert-butoxycarbonyl)allylglycine-N-methoxy-N-methylamide
• 英文别名: tert-butyl (1-(methoxy(methyl)amino)-1-oxopent-4-en-2-yl)carbamate；1,1-dimethylethyl ((1RS)-1-{[methyl(methyloxy)amino]carbonyl}-3-buten-1-yl)carbamate；tert-Butyl 1-{[methoxy(methyl)amino]carbonyl}-3-butenylcarbamate；tert-butyl N-[1-[methoxy(methyl)amino]-1-oxopent-4-en-2-yl]carbamate
• CAS: 603992-62-7
• 化学式: C₁₂H₂₂N₂O₄
• 分子量: 258.318
• InChiKey: ABXBWUPWFQLRRK-UHFFFAOYSA-N

物化性质

• 密度：
  1.053±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N^α-(tert-butoxycarbonyl)allylglycine-N-methoxy-N-methylamide 在 platinum on activated charcoal lithium hydroxide 、 lithium aluminium tetrahydride 、 Grubbs catalyst first generation 、 三氟甲磺酸二丁硼 、 氢气 、 双氧水 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 二氯甲烷 为溶剂， 反应 96.75h， 生成
  参考文献：
  名称：

  Conformationally Constrained Analogues of Bleomycin A₅

  摘要：

  The bleomycin (BLM) group antitumor antibiotics are glycopeptide-derived natural products shown to cause sequence selective lesions in DNA. Prior studies have indicated that the linker region, composed of the methylvalerate and threonine residues, may be responsible for a conformational bend in the agent required for efficient DNA cleavage. We have synthesized a number of conformationally constrained methylvalerate analogues and incorporated them into deglycobleomycin A(5) congeners using our recently reported procedure for the solid phase construction of (deglyco)bleomycin and its analogues. These analogues were designed to probe the effects of conformational constraint of the native valerate moiety. Initial experiments indicated that the constrained molecules, none of which mimic the conformation proposed for the natural valerate linker, possessed DNA cleavage activity, albeit with potencies less than that of (deglyco)BLM and lacking sequence selectivity. Further experiments demonstrated that these analogues failed to produce alkali-labile lesions in DNA or sequence selective oxidative damage in RNA. However, two of the conformationally constrained deglycoBLM analogues were shown to mediate RNA cleavage in the absence of added Fe2+. The ability of the analogues to mediate the oxygenation of small molecules was also assayed, and it was shown that they were as competent in the transfer of oxygen to low molecular weight substrates as the parent compound.

  DOI：

  10.1021/ja030057w
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 N,N'-羰基二咪唑 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 9.67h， 生成 N^α-(tert-butoxycarbonyl)allylglycine-N-methoxy-N-methylamide
  参考文献：
  名称：

  [EN] PESTICIDAL AND HERBICIDAL COMPOUNDS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS PESTICIDES ET HERBICIDES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  The present invention relates to novel a pesticidally and/or herbicidally active compounds, agrochemical composition thereof, methods of preparation thereof, and uses thereof for controlling the growth of undesirable plants (e.g., weeds), for example in crop fields.

  公开号：

  WO2023181030A1

文献信息

• [EN] BENZIMIDAZOLE ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX À BASE DE BENZIMIDAZOLE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011097491A1

  公开（公告）日：2011-08-11

  Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是公式(I)和(II)的化合物以及它们的药用可接受盐，它们的药物组合物，它们的制备方法，以及它们用于治疗由黄病毒科病毒家族成员如丙型肝炎病毒（HCV）介导的病毒感染。
• [EN] ALIPHATIC PROLINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE PROLINAMIDE ALIPHATIQUE
  申请人：INCEPTION 4 INC

  公开号：WO2017222917A1

  公开（公告）日：2017-12-28

  This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the invention are also useful for inhibiting HTRAl protease activity in an eye or locus of an arthritis or related condition.

  这项发明涉及一种新型的脂肪族脯氨酰胺衍生物，其化学式为I，并且包括药学上可接受的盐、溶剂化合物、盐的溶剂化合物和其前药，用于预防（例如，延缓或减少发展风险）和治疗（例如，控制、缓解或减缓进展）与眼睛相关的年龄相关性黄斑变性（AMD）及相关眼部疾病。这些疾病包括干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受器细胞的退化。本公开的发明还涉及预防、减缓进展和治疗干性AMD、湿性AMD和地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受器细胞的方法，包括：给予所述发明化合物的治疗有效量。本发明的化合物是HTRAl的抑制剂。因此，本发明的化合物在预防和治疗一系列（全部或部分）由HTRAl介导的疾病中具有用途。本发明的化合物还可用于抑制眼部或关节炎或相关疾病部位的HTRAl蛋白酶活性。
• ORGANIC COMPOUNDS AND THEIR USES
  申请人：Brandl Trixl

  公开号：US20100204159A1

  公开（公告）日：2010-08-12

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

  本申请描述了对人类疾病的治疗、预防和/或改善有用的有机化合物。
• Method of treating resistant tumors
  申请人：Wyeth Holdings Corporation

  公开号：US20040121965A1

  公开（公告）日：2004-06-24

  The invention provides a method of treating or inhibiting the growth of or eradicating a tumor in a mammal in need thereof wherein said tumor is resistant to at least one chemotherapeutic agent which method comprises providing to said mammal an effective amount of a compound of Formula II or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗或抑制哺乳动物体内对至少一种化疗药物产生耐药性的肿瘤生长或根除肿瘤的方法，该方法包括向该哺乳动物提供有效量的公式II化合物或其药学上可接受的盐。
• Aliphatic prolinamide derivatives
  申请人：ORION OPHTHALMOLOGY LLC

  公开号：US10730832B2

  公开（公告）日：2020-08-04

  This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.

  本发明涉及式I的新型脂肪族丙氨酰胺衍生物及其药学上可接受的盐、溶液剂、盐的溶解物和原药，可用于预防（如延缓发病或降低发病风险）和治疗（如控制、减轻或延缓进展）老年性黄斑变性（AMD）及相关眼部疾病。这些疾病包括干性黄斑变性、湿性黄斑变性、地理萎缩、糖尿病视网膜病变、早产儿视网膜病变、多形性脉络膜血管病变以及视网膜或感光细胞变性。本文公开的本发明进一步涉及预防、减缓干性-AMD、湿性-AMD 和地理萎缩、糖尿病视网膜病变、早产儿视网膜病变、多形性脉络膜血管病变以及视网膜或感光细胞变性的进展和治疗方法，包括：施用治疗有效量的本发明化合物。本发明化合物是 HTRA1 的抑制剂。因此，本发明化合物可用于预防和治疗由 HTRA1（全部或部分）介导的多种疾病。本发明的化合物还可用于抑制关节炎或相关疾病的眼部或病灶中的 HTRA1 蛋白酶活性。